CTLA4 and cutaneous mastocytosis: Although ICB therapy targeting the PD-1/PD-L1 axis and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) has shown dramatic improvement in survival rate for many CM patients (Khunger et al., 2019), meaningful clinical responses have only been observed in a relatively small subset of patients.